April 21, 2026Press releasesDewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026
February 11, 2026Press releasesDewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate
February 4, 2026Press releasesDewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
January 13, 2026News updatesExcitement and confidence at Dewpoint in TDP-43 condensate modulator development candidate
January 8, 2026Press releasesDewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment of ALS and Related Neurodegenerative Diseases
January 6, 2026Press releasesDewpoint Therapeutics Launches Initiative to Build Viral Condensate Phenomics Atlas for HPV
November 17, 2025Press releasesFDA Grants Fast Track Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
October 29, 2025Press releasesFDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
